But due to their detection ratios, P/LP variants in BRCA1/2 and other homologue recombination repair genes represent an important indication for PARP inhibitor therapy in breast, ovarian, pancreatic, and prostate cancer [1]. The gene discussed is BRCA1; the disease is Familial prostate cancer.